top of page

Italy's Drug Agency Approves Reimbursement for Filspari, Dawnzera, Exdensur, Lynkuet, and Expanded Uses of Aspaveli and Gazyvaro

Badari Andukuri
1 hour ago
2 min read

During its November 18, 2026 session, the governing board of the Italian Medicines Agency (AIFA) authorized National Health Service (SSN) coverage across a broad portfolio of treatments, ranging from rare kidney disease therapies and novel active substances to expanded clinical uses and generic alternatives. Alongside these coverage expansions, regulators finalized price renegotiations for existing therapies, securing 7.4 million euros in pharmaceutical budget savings.


Rare Disease Coverage

Filspari (sparsentan):

Italian regulators granted orphan drug coverage for this oral tablet therapy targeting adults living with primary immunoglobulin A (IgA) nephropathy. This progressive autoimmune condition steadily impairs renal function, often leading to end-stage kidney failure that requires ongoing dialysis or organ transplantation.


Novel Active Substances

Three first-time molecular entities gained public funding approval across immunology, respiratory care, and oncology support:

  • Dawnzera (donidalorsen): Authorized for ongoing prophylactic care to prevent recurring swelling episodes in individuals aged 12 and older diagnosed with hereditary angioedema.

  • Exdensur (depemokimab): Approved for dual respiratory uses. It will serve as supplementary maintenance care for patients aged 12 and older experiencing uncontrolled severe asthma linked to type 2 eosinophilic inflammation. Additionally, it gained backing as an add-on to nasal steroids for adults battling severe chronic rhinosinusitis with nasal polyps when systemic steroids or surgical interventions fail.

  • Lynkuet (elinzanetant): Cleared to relieve moderate-to-severe hot flashes and night sweats triggered by hormone-blocking breast cancer therapies.


Expanded Therapeutic Uses and Dosing Updates

Regulators broadened clinical access across nephrology, infectious disease, neurology, and pediatric care:


Aspaveli (pegcetacoplan): Earned official therapeutic innovation status alongside reimbursement for patients aged 12 and older diagnosed with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN). Clinicians will prescribe it alongside renin-angiotensin system (RAS) inhibitors, except where patients cannot tolerate or have contraindications to RAS blockers.


Gazyvaro (obinutuzumab): Cleared for public funding when paired with mycophenolate mofetil (MMF) to manage adults with active Class III or IV lupus nephritis.


Recarbrio (imipenem with enzyme inhibitors): This intravenous antibiotic received extended coverage down to newborn infants hospitalized with severe, carbapenem-resistant Gram-negative bacterial infections, including bloodstream infections and hospital-acquired or ventilator-associated pneumonia.


Stelara (ustekinumab): Expanded into pediatric gastroenterology for children weighing 40 kg or more who face moderate-to-severe active Crohn's disease and have not responded to, or cannot tolerate, standard or biologic regimens.


Spinraza (nusinersen): Regulators accepted and authorized an updated dosing protocol for this therapy targeting 5q spinal muscular atrophy (SMA).

Recent Posts

See All

Comments


Join our mailing list

bottom of page